Scarica l'app Stockscreener
20.36
2.16%
0.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Stocktwits
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
Behavioral Patterns of MLTX and Institutional Flows - Stock Traders Daily
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout | AI
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
MoonLake Immunotherapeutics' CFO Sells 39K Shares - The Motley Fool
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits
Insider Sell: Santos da Silva Jorge Sells 47,775 Shares of MoonL - GuruFocus
CEO of MoonLake Immunotherapeutics (NASDAQ: MLTX) sells shares under plan - Stock Titan
Class Action Lawsuit Filed Against MoonLake Immunotherapeutics (M - The National Law Review
MoonLake Reports Positive 52-Week Phase 3 Data for Sonelokimab in Hidradenitis Suppurativa - Dermatology Times
Top biotech stocks to watch in second half of 2026, says Clear Street - Investing.com South Africa
MLTX Maintained by Leerink Partners -- Price Target Raised to $2 - GuruFocus
Leerink raises Moonlake stock price target on HS drug data By Investing.com - Investing.com South Africa
Leerink raises Moonlake stock price target on HS drug data - Investing.com
Form 144 MoonLake Immunotherapeutics For: 30 June By Investing.com - Investing.com South Africa
MLTX (Nasdaq) Rule 144 notice shows 150,000 Class A shares sale (04/10/2026) - Stock Titan
MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa - Yahoo Finance
MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism? - Stocktwits
Form 13D/A MoonLake Immunotherapeutics For: 29 June By Investing.com - Investing.com South Africa
BVF group reports 19.7% MoonLake Immunotherapeutics (MLTX) stake - Stock Titan
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Chart - ChartMill
MoonLake Immunotherapeutics (MLTX) Is Down 10.2% After $200M Follow-On Offering To Fund Sonelokimab PushHas The Bull Case Changed? - simplywall.st
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Ove - The National Law Review
MoonLake Immunotherapeutics Completes $200 Million Public Offering of Class A Shares - Global Legal Chronicle
Did You Lose Money on MoonLake Immunotherapeutics (MLTX)? Levi - The National Law Review
Join Class Action to Recover Losses from MoonLake Immunotherapeut - The National Law Review
Levi & Korsinsky Urges MoonLake (MLTX) Shareholders to Act Before Lead Plaintiff Deadline December 15, 2025 - The National Law Review
MoonLake Immunotherapeutics (MLTX) Investigation: Bronstein, Gewi - The National Law Review
Securities Fraud Class Action Filed Against MoonLake Immunotherap - The National Law Review
Recover Investment Losses: Class Action Initiated Against MoonLake Immunotherapeutics (MLTX) - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating MoonLake Immu - The National Law Review
Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Acti - The National Law Review
Shareholders of MoonLake Immunotherapeutics (MLTX): Protect Your - The National Law Review
MLTX ALERT: Block & Leviton LLP Announces The Filing of a Class A - The National Law Review
10 Best Biotech Stocks to Buy According to Analysts - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
MoonLake Immunotherapeutics (MLTX) LawsuitInvestors Urged to C - The National Law Review
Levi & Korsinsky Invites Investors to SueWallSt After MoonLake Immunotherapeutics Stock Collapse - The National Law Review
MLTX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
MLTX stock extends pullback after biggest rally in over 6 months following skin disease trial data — a look at the latest development - MSN
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday - AOL.com
MoonLake Immunotherapeutics Class A Actuals & Estimates (NASDAQ:MLTX) - TradingView
Why MoonLake Immunotherapeutics stock wilted on Wednesday - MSN
(MLTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion (NASDAQ:MLTX) - Seeking Alpha
MoonLake Immunotherapeutics prices $200M public offering of Class A shares - MSN
Enterprise value to EBIT forward of MoonLake Immunotherapeutics – NASDAQ:MLTX - TradingView
MoonLake Expects Offering to Close on or About June 25 >MLTX - Moomoo
United StatesMintz Advises On MoonLake Immunotherapeutics’ $200 Million Public Offering - Mondaq
Enterprise value to EBIT forward of MoonLake Immunotherapeutics – BOATS:MLTX - TradingView
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):